Este artículo revisa los principales avances publicados o comunicados durante el año 2004 en la fisiopatología, la prevención secundaria, el pronóstico y el tratamiento de los síndromes coronarios agudos con y sin elevación del segmento ST, así como las nuevas guías de práctica clínica.
Palabras clave
Síndromes coronarios agudos
Infarto de miocardio
Fisiopatología
Prevención
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
I.P. Garrido, D. Roy, R. Calvino, J.M. Vázquez-Rodríguez, G. Aldama, J. Cosin-Sales, et al.
Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals.
Am J Cardiol, (2004), 93 pp. 88-90
[2.]
M.L. Brennan, M.S. Penn, F. Van Lente, V. Nambi, M.H. Shishehbor, R.J. Aviles, et al.
Prognostic value of myeloperoxidase in patients with chest pain.
N Engl J Med, (2003), 349 pp. 595-604
[3.]
J.A. Vita, M.L. Brennan, N. Gokce, S.A. Mann, M. Goormastic, M.H. Shishehbor, et al.
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.
Circulation, (2004), 110 pp. 1134-1139
[4.]
M. Magnusson, O. Melander, B. Israelsson, A. Grubb, L. Groop, S. Jovinge.
Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease.
Diabetes Care, (2004), 27 pp. 1929-1935
[5.]
M.A. Bhalla, A. Chiang, V.A. Epshteyn, R. Kazanegra, V. Bhalla, P. Clopton, et al.
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus.
J Am Coll Cardiol, (2004), 44 pp. 1047-1052
[6.]
J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, et al.
C - reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
N Engl J Med, (2004), 350 pp. 1387-1397
[7.]
S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
Lancet, (2004), 364 pp. 937-952
[8.]
A.M. Gotto Jr, E.A. Brinton.
Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update.
J Am Coll Cardiol, (2004), 43 pp. 717-724
[9.]
G. Assmann, A.M. Gotto Jr.
HDL cholesterol and protective factors in atherosclerosis.
Circulation, (2004), 109 pp. 8-14
[10.]
L.O. Martínez, S. Jacquet, F. Terce, X. Collet, B. Perret, R. Barbaras.
New insight on the molecular mechanisms of high-density lipoprotein cellular interactions.
Cell Mol Life Sci, (2004), 61 pp. 2343-2360
[11.]
R.P. Choudhury, J.X. Rong, E. Trogan, V.I. Elmalem, H.M. Dansky, J.L. Breslow, et al.
High-density lipoprotein retards the progression of atherosclerosis and favorably remodels lessions without suppressing indices of inflammation or oxidation.
Arterioscler Thromb Vasc Biol, (2004), 24 pp. 1904-1909
[12.]
G.S. Getz, C.A. Reardon.
Paraoxonase, a cardioprotective enzyme: continuing issues.
Curr Opin Lipidol, (2004), 15 pp. 261-267
[13.]
R.W. Clark, T.A. Sutfin, R.B. Ruggeri, A.T. Willauer, E.D. Sugarman, G. Magnus-Aryitey, et al.
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
Arterioscler Thromb Vasc Biol, (2004), 24 pp. 490-497
[14.]
G.J. De Grooth, A.H. Klerkx, E.S. Stroes, A.F. Stalenhoef, J.J. Kastelein, J.A. Kuivenhoven.
What can we expect from inhibition of CETP activity in the treatment of dyslipidemia?.
J Lipid Res, (2004), 45 pp. 1967-1974
[15.]
C.D. Meyers, M.L. Kashyap.
Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
Curr Opin Cardiol, (2004), 19 pp. 366-373
[16.]
L. Rohrer, M. Hersberger, A. Von Eckardstein.
High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease.
Curr Opin Lipidol, (2004), 15 pp. 269-278
[17.]
C. Wadham, N. Albanese, J. Roberts, L. Wang, C.J. Bagley, J.R. Gamble, et al.
High-density lipoproteins neutralize C-reactive protein proinflammatory activity.
Circulation, (2004), 109 pp. 2116-2122
[18.]
GAMI. Glucose Abnormalities in patients with Myocardial Infarction—prevalence, diagnosis and prognostic implications. Presentación oral en el Congreso de la ESC. Múnich, agosto 2004.
[19.]
PROVE-IT TIMI 22 trial. Presentación oral en el Congreso de la ESC. Múnich, agosto 2004.
[20.]
J.T. Grayston, R. Kronmal, L.A. Jackson, A.F. Parisi, J.B. Muhlestein, J.D. Cohen, et al.
Antibiotic treatment for secondary prevention of coronary events. Results of the Azithromycin and Coronary Events Study (ACES).
Presentación oral en el Congreso de la Sociedad Europea de Cardiología,
[21.]
F. Fernández Avilés, J.A. San Román, J.G. García Frade, M. Valdés, A. Sánchez, L. De la Fuente, et al.
Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio.
Rev Esp Cardiol, (2004), 57 pp. 201-208
[22.]
J. Critchley, S. Capawell.
Smoking cessation for secondary prevention of coronary disease.
Cochrane Database Syst Rev, (2004),
[23.]
A.P. Whelton, J. He, P.K. Whelton, P. Muntner.
Meta-analysis of observatinal studies on fish intake and coronary heart disease.
Am J Cardiol, (2004), 93 pp. 1119-1123
[24.]
C.M. Yo, L.S. Li, M.F. Lam, D.C. Siu, R.K. Miu, C.P. Lau.
Effect of a cardiac rehabilitation programm on left ventricular diastolic function and its relationship to excercise capacity in patients with coronary heart disease: experience from a randomized, controlled study.
Am Heart J, (2004), 147 pp. e24
[25.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, (2004), 350 pp. 1495-1504
[26.]
J.A. De Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A.A. Fox, H.D. White.
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial.
JAMA, (2004), 292 pp. 1307-1316
[27.]
E. Braunwald, M.J. Domanski, S.E. Fowler, N.L. Geller, B.J. Gersh, J. Hsia, et al.
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. PEACE Trial.
N Engl J Med, (2004), 351 pp. 2058-2068
[28.]
P.M. Ho, F.A. Masoudi, E.D. Peterson, G.K. Grunwald, A.E. Sales, K.E. Hammermeister, et al.
Cardiology management improves secondary prevention measures among patients with coronary artery disease.
J Am Coll Cardiol, (2004), 43 pp. 1517-1523
[29.]
K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, F. Van de Werf, et al.
A Validated prediction model for all forms of acute coronary syndrome estimating the risk of 6-month postdischarge death in an international registry.
JAMA, (2004), 291 pp. 2727-2733
[30.]
C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, et al.
Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. Grupo de Trabajo sobre el uso de agentes antiplaquetarios en pacientes con enfermedad cardiovascular aterosclerótica de la Sociedad Europea de Cardiología.
Rev Esp Cardiol, (2004), 57 pp. 963-980
[31.]
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126 Suppl 3:172S-3S.
[32.]
The SYNERGY Trial Investigators.
Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy primary results of the SYNERGY randomized trial.
JAMA, (2004), 292 pp. 45-54
[33.]
M.A. Blazing, J.A. De Lemos, H.D. White, K.A. Fox, F.W. Verheugt, D. Ardissino, et al.
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
JAMA, (2004), 292 pp. 55-64
[34.]
J.L. Petersen, K.W. Mahaffey, V. Hasselblad, E.M. Antman, M. Cohen, S.G. Goodman.
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes A systematic overview.
JAMA, (2004), 292 pp. 89-96
[35.]
M.S. Sabatine, D.A. Morrow, R.P. Giugliano, S.A. Murphy, L.A. Demopoulos, P.M. DiBattiste, et al.
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction. A comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB Trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 Trial.
Circulation, (2004), 109 pp. 874-880
[36.]
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, et al.
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS.
Eur Heart J, (2004), 25 pp. 1494-1501
[37.]
R.G. Bach, C.P. Cannon, W.S. Weintraub, P.M. DiBattiste, L.A. Demopoulos, H.V. Anderson, et al.
The effect of routine, early invasive management on outcome for elderly patients with non–ST-segment elevation acute coronary syndromes.
Ann Intern Med, (2004), 141 pp. 186-195
[38.]
T.C. Clayton, S.J. Pocock, R.A. Henderson, P.A. Poole-Wilson, T.R. Shaw, R. Knight, et al.
Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial.
Eur Heart J, (2004), 25 pp. 1641-1650
[39.]
E.M. Antman, D.T. Anbe, P.W. Armstrong, E.R. Bates, L.A. Green, M. Hand, et al.
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the management of patients with acute myocardial infarction).
J Am Coll Cardiol, (2004), 44 pp. 671-719
[40.]
E.C. Keely, J.A. Boura, C.L. Grines.
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
Lancet, (2003), 361 pp. 13-20
[41.]
Silber S, Albertrsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. European Guidelines for Percutaneous Coronary Interventions (PCI). Eur Heart J. 2005: en prensa.
[42.]
F. Fernández-Avilés, J.J. Alonso, A. Castro Beiras, F.J. Goicolea, J. Blanco, J. Alonso Briales, et al.
Angioplastia primaria con stent versus facilitada (trombólisis con tenecteplase seguida de ACTPStent) en pacientes con IAM y elevación del segmento ST. Estudio GRACIA 2.
Rev Esp Cardiol, (2003), 56 pp. 147
[43.]
A. Kastrati, J. Mehilli, K. Schlotterbeck, F. Dotzer, J. Dirschinger, C. Schmitt, et al.
Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for pecutaneous coronary intervention.
JAMA, (2004), 291 pp. 947-954
[44.]
D. Antoniuci, A. Migliorini, G. Parodi, R. Valenti, A. Rodriguez, A. Hempel, et al.
Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survial. A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
Circulation, (2004), 109 pp. 1704-1706
[45.]
D.P. Lee, N.A. Herity, B.L. Hiatt, W.F. Fearon, M. Rezaee, A.J. Carter, et al.
Adjuntive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes. Results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
Circulation, (2003), 107 pp. 1497-1501
[46.]
A.W.J. Van’t Hof, N. Ernst, M.J. De Boer, R. de Winter, E. Boersma, T. Bunt, et al.
Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (ON-TIME) trial.
Eur Heart J, (2004), 25 pp. 837-846
[47.]
H.J. Büttner, F.J. Neumann.
Tirofiban for catheter intervention in acute myocardial infarction?.
Eur Heart J, (2004), 25 pp. 807-809
[48.]
D. Hasdai, S. Behar, L. Wallentin, N. Danchin, A.K. Gitt, E. Boersma, et al.
A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (euro Heart Survey ACS).
Eur Heart J, (2002), 23 pp. 1190-1201
[49.]
D.A. Morrow, E.M. Antman, L. Parsons, J.A. De Lemos, C.P. Cannon, R.P. Giugliano, et al.
Application of the TIMI risk score for STelevation MI in the National Registry of Myocardial Infarction 3.
JAMA, (2001), 286 pp. 1356-1359
[50.]
E. Bonneffoy, F. Lapostolle, A. Leizorovicz, G. Steg, E.P. McFadden, P.Y. Dubien, et al.
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.
Lancet, (2002), 360 pp. 825-829
[51.]
P.G. Steg, E. Bonnefoy, S. Chabaud, F. Lapostolle, P.Y. Dubien, P. Cristofini, et al.
Impact of the time to treatment on mortality after preshospital fibrinolysis or primary angioplasty. Data from the CAPTIM randomized clinical trial.
Circulation, (2003), 108 pp. 2851-2856
[52.]
G. De Luca, H. Suryapranata, J.P. Ottervanger, E.M. Antman.
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Every minute of delay counts.
Circulation, (2004), 109 pp. 1223-1225
[53.]
F. Van de Werf, D. Ardissino, A. Betriu, D.V. Cokkinos, E. Falk, K.A. Fox, et al.
Management of acute myocardial infarction in patients presenting with ST segment elevation. The Task Force on the management of acute myocardial infarction of the European Society of Cardiology.
Eur Heart J, (2003), 24 pp. 28-66
[54.]
F. Fernández-Avilés, J.J. Alonso, A. Castro-Beiras, N. Vázquez, J. Blanco, J. Alonso-Briales, et al.
Routine invasive strategy within 24 hours of trombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial.
Lancet, (2004), 364 pp. 1045-1053
[55.]
B. Scheller, B. Hennen, B. Hammer, J. Walle, C. Hofer, V. Hilpert, et al.
Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.
J Am Coll Cardiol, (2003), 42 pp. 634-641
[56.]
K.C. Wollert, G.P. Meyer, J. Lotz, S. Ringes-Lichtenberg, P. Lippolt, C. Breidenbach, et al.
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.
Lancet, (2004), 364 pp. 141-148
[57.]
F. Fernández-Aviles, J.A. San Román, J. García-Frade, M.E. Fernández, M.J. Peñarrubia, L. De la Fuente, et al.
Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction.
Circ Res, (2004), 95 pp. 742-748
Copyright ©
2005. Sociedad Española de Cardiología